SCHEMBL10255406

SCHEMBL10255406

CCS(=O)(=O)N1CCN(c2cncc(-c3nnc(-c4ccco4)o3)n2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
ALDH1A1 P00352 12/20 0.41
KDM4E B2RXH2 9/20 0.41
MEN1 O00255 2/20 0.39
LMNA P02545 2/20 0.39
MAPK1 P28482 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 2/20 0.39
PKM P14618 1/20 0.39
POLB P06746 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HPGD P15428 7/20 0.39
HSD17B10 Q99714 7/20 0.39
RAB9A P51151 5/20 0.38
NPC1 O15118 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
TP53 P04637 3/20 0.38
TSHR P16473 3/20 0.38
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10255858 0.84 KMT2A (0.52) MAPTALDH1A1KDM4EMEN1LMNA
SCHEMBL10256552 0.81 HSD17B10 (0.44) MAPTALDH1A1KDM4EMEN1LMNA
SCHEMBL10255365 0.81 NPC1 (0.44) MAPTALDH1A1KDM4EMEN1LMNA
SCHEMBL2529491 0.81 ATR (0.50) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL10255396 0.80 MEN1 (0.43) MAPTALDH1A1KDM4EMEN1LMNA
SCHEMBL10255529 0.80 HSD17B10 (0.46) MAPTALDH1A1KDM4EMEN1LMNA
SCHEMBL10255382 0.80 MAPK1 (0.43) MAPTALDH1A1KDM4EMEN1LMNA
SCHEMBL10256692 0.79 MAPK1 (0.42) MAPTALDH1A1KDM4EMEN1LMNA
SCHEMBL10255493 0.78 KMT2A (0.40) MAPTALDH1A1KDM4EMEN1LMNA
SCHEMBL10255565 0.77 ATR (0.41) MAPTALDH1A1KDM4EMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 MAPT 3458/4885ALDH1A1 3958/4885KDM4E 2868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.